Regeneron shareholders elect directors, approve executive compensation at 2024 annual meeting

REGENERON PHARMACEUTICALS, INC.

Class III directors elected: N.A. Coles, K. Guarini, A.F. Ryan, G.L. Sing; Class II director D.P. Schenkein elected.
Ratification of PwC as auditor for FY2024: 111.4M for, 5.3M against, 60.6K abstain.
Advisory vote on executive compensation passed: 106.7M for, 5.6M against, 207.5K abstain, 4.2M broker non-votes.
Non-binding shareholder proposal requesting simple majority voting approved: 85.9M for, 26.4M against, 188.7K abstain.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.